Aim. We evaluated the effects of botulinum toxin type A (BTA)–abobotulinumtoxinA on
passive motion resistance (PMR) values of lower limbs affected muscles and on the …

Background Spasticity is the most frequent alteration in muscle tone in cerebral palsy (CP),
but it can also represent a functional compensation. Moreover, apparently similar contraction …

Background: Cerebral palsy (CP) is one of the most common causes of activity limitation in
children. Botulinum toxin (BoNT-A) is relatively recent addition to the available medical …

One of the main goals when treating spasticity is to relieve pain and improve function.
Intramuscular injection of botulinum toxin type A (BTX‐A) has gained widespread …

Introduction Spasticity has been considered to be a main contributor to both the impairment
of function as well as posture in children with cerebral palsy (CP). Patterns of upper limb …

INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children.
Spasticity is a disabling clinical symptom that is prevalent among patients suffering from …

Objective: To evaluate whether botulinum toxin type A injections improve upper limb function
in children with cerebral palsy. Methods: An extensive search was carried out in PUBMED …

Botulinum toxin A is widely used for spasticity management in children with cerebral palsy,
although outcomes are unpredictable. The aim of this study was to identify criteria for …

Spasticity and muscle weakness is common in children with cerebral palsy (CP). Spasticity
can be treated with botulinum neurotoxin-A (BoNT-A), but this drug has also been reported …

Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic
cerebral palsy, but its added value preceding comprehensive rehabilitation for motor …